Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

2024-510980-40-00 Protocol Debio 0123-SCLC-104 Human pharmacology (Phase I) - Other Ended

Start 9 Mar 2023 · End 10 Mar 2026 · Status Ended · 1 EU/EEA countries · 12 sites · Protocol Debio 0123-SCLC-104

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 78
Countries 1
Sites 12

Small cell lung cancer

Key facts

Sponsor
Debiopharm International SA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Mar 2023 → 10 Mar 2026
Decision date (initial)
2024-07-12
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-510980-40-00
EudraCT number
2022-001976-32
WHO UTN
U1111-1302-8787
ClinicalTrials.gov
NCT05815160

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Small cell lung cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10041067 Small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Debiopharm International SA

Sponsor organisation
Debiopharm International SA
Address
Forum Apres-Demain, Chemin Messidor 5-7 Chemin Messidor 5-7
City
Lausanne
Postcode
1006
Country
Switzerland

Scientific contact point

Organisation
Debiopharm International SA
Contact name
Clinical department

Public contact point

Organisation
Debiopharm International SA
Contact name
Clinical department

Locations

1 EU/EEA country · 12 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 50 12
Rest of world
United States
28

Investigational sites

Spain

12 sites · Ended
Clinica Universidad De Navarra
Medical Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Clinic De Barcelona
Medical Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Clinico Universitario De Valencia
Medical Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Complexo Hospitalario Universitario A Coruna
Medical Oncology, Lugar Jubias De Arriba 84, 15006, A Coruna
Institut Catala D'oncologia
Medical Oncology, Carretera Canyet S/n, 08916, Badalona
Hospital Universitario Hm Sanchinarro
Medical Oncology, Calle Ona 10, 28050, Madrid
Hospital Quironsalud Malaga
Oncology, Avenida Imperio Argentina 1, 29004, Malaga
Hospital Universitario 12 De Octubre
Medical Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Clinica Universidad De Navarra
Medical Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital General Universitario Gregorio Maranon
Medical Oncology, Calle Del Doctor Esquerdo 46, 28007, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2023-03-09 2023-05-02 2025-07-21

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-92673

Halt date
2025-07-21
Member states concerned
Spain
Publication date
2025-07-31
Reason
Safety related (clinical or pre-clinical results)
Follow-up measures
No follow-up measures for subjects are considered necessary.
Benefit-risk balance changed
Yes
Treatment stopped
No

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-21 Spain Acceptable with conditions
2024-07-12
2024-07-12
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-06 Spain Acceptable
2024-10-21
2024-11-08
3 SUBSTANTIAL MODIFICATION SM-2 2025-01-31 Spain Acceptable
2025-03-14
2025-03-14
4 SUBSTANTIAL MODIFICATION SM-3 2025-04-16 Spain Acceptable 2025-05-22
5 SUBSTANTIAL MODIFICATION SM-5 2025-09-23 Spain Acceptable
2025-11-07
2025-11-12